Data from the LUX-Lung clinical trial programme, investigating Giotrif/Gilotrif (afatinib)from Boehringet in patients with advanced Non-Small Cell Lung Cancer (NSCLC),...
Boehringer Ingelheim announced the results of the LUX-Lung 7 trial, a Phase IIb trial of Giotrif (afatinib) in patients with...
Results from a new post-hoc analysis of two large Phase III trials (LUX-Lung 3 and LUX-Lung 6) assessing the impact...
LUX-Lung 3, the pivotal Phase III clinical trial investigating Tomtovok (afatinib), from Boehringer, in patients with stage IIIB or IV...
Boehringer announced that the European Commission (EC) has granted marketing authorisation for Giotrif (afatinib) for the treatment of patients with...
Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency for approval of Tomtovok...
The European Commission has granted marketing authorisation for Giotrif (afatinib), from Boehringer, for the treatment of patients with metastatic Non-Small...
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients...
Boehringer Ingelheim announced that The Lancet Oncology has published results from the LUX-Lung 8 trial (NCT01523587) of Giotrif (afatinib) in...
The FDA and the European Medicines Agency (EMA) have accepted filing applications for Giotrif/Gilotrif (afatinib), from Boehringer Ingelheim, for the...